155 related articles for article (PubMed ID: 16375692)
1. Molecular basis of therapeutic strategies for breast cancer.
Huang J; Li X; Hilf R; Bambara RA; Muyan M
Curr Drug Targets Immune Endocr Metabol Disord; 2005 Dec; 5(4):379-96. PubMed ID: 16375692
[TBL] [Abstract][Full Text] [Related]
2. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
3. Therapeutic targeting in the estrogen receptor hormonal pathway.
Katzenellenbogen BS; Frasor J
Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
[TBL] [Abstract][Full Text] [Related]
4. Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer.
Nott SL; Huang Y; Kalkanoglu A; Harper K; Chen M; Paoni SF; Fenton BM; Muyan M
Mol Med; 2010; 16(1-2):10-8. PubMed ID: 19946606
[TBL] [Abstract][Full Text] [Related]
5. The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer.
Spears M; Bartlett J
Expert Opin Ther Targets; 2009 Jun; 13(6):665-74. PubMed ID: 19456271
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptors and their downstream targets in cancer.
Ikeda K; Inoue S
Arch Histol Cytol; 2004 Dec; 67(5):435-42. PubMed ID: 15781984
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy--current benefits and limitations.
Nicholson RI; Johnston SR
Breast Cancer Res Treat; 2005; 93 Suppl 1():S3-10. PubMed ID: 16247594
[TBL] [Abstract][Full Text] [Related]
8. Estrogen signaling and unfolded protein response in breast cancer.
Rajapaksa G; Thomas C; Gustafsson JÅ
J Steroid Biochem Mol Biol; 2016 Oct; 163():45-50. PubMed ID: 27045680
[TBL] [Abstract][Full Text] [Related]
9. Cracking the estrogen receptor's posttranslational code in breast tumors.
Le Romancer M; Poulard C; Cohen P; Sentis S; Renoir JM; Corbo L
Endocr Rev; 2011 Oct; 32(5):597-622. PubMed ID: 21680538
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
Wang ZY; Yin L
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.
Gougelet A; Bouclier C; Marsaud V; Maillard S; Mueller SO; Korach KS; Renoir JM
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):71-81. PubMed ID: 15862952
[TBL] [Abstract][Full Text] [Related]
13. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells.
Chang EC; Frasor J; Komm B; Katzenellenbogen BS
Endocrinology; 2006 Oct; 147(10):4831-42. PubMed ID: 16809442
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients.
Cappelletti V; Celio L; Bajetta E; Allevi A; Longarini R; Miodini P; Villa R; Fabbri A; Mariani L; Giovanazzi R; Galante E; Greco M; Grazia Daidone M
Endocr Relat Cancer; 2004 Dec; 11(4):761-70. PubMed ID: 15613450
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.
Normanno N; Di Maio M; De Maio E; De Luca A; de Matteis A; Giordano A; Perrone F;
Endocr Relat Cancer; 2005 Dec; 12(4):721-47. PubMed ID: 16322319
[TBL] [Abstract][Full Text] [Related]
16. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?
Murphy LC; Watson PH
Endocr Relat Cancer; 2006 Jun; 13(2):327-34. PubMed ID: 16728566
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
18. The biological role of estrogen receptors alpha and beta in cancer.
Pearce ST; Jordan VC
Crit Rev Oncol Hematol; 2004 Apr; 50(1):3-22. PubMed ID: 15094156
[TBL] [Abstract][Full Text] [Related]
19. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells.
Lee SO; Nadiminty N; Wu XX; Lou W; Dong Y; Ip C; Onate SA; Gao AC
Cancer Res; 2005 Apr; 65(8):3487-92. PubMed ID: 15833885
[TBL] [Abstract][Full Text] [Related]
20. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
